Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to introduce the team appointed to conduct clinical trials of its insomnia products using Blake's proprietary Zleepaxtm formula:

• Christian Schutz ? Medical Director
  Dr. Schutz received an MD from Albert Ludwigs University in Freiburg, Germany, a PhD from Ludwig Maximilians University in Munich and a Master of Public Health from Johns Hopkins University. He held a Fellowship in Behavioural Pharmacology from the National Institute on Drug Abuse at the National Institutes of Health in Baltimore and, while on sabbatical, studied Clinical Neuroscience at Yale University. He currently serves as an Associate Professor at UBC's Faculty of Medicine in the Department of Psychiatry.

• Ajit Johal ? Clinical Trial Sponsor
  Mr. Johal is a graduate from the Leslie Dan Faculty of Pharmacy at the University of Toronto. He is the clinical services coordinator at Wilson Pharmacy in Port Coquitlam and is a clinical instructor at UBC's Faculty of Pharmaceutical Sciences. He has worked as lead clinical pharmacist for a number of outreach programs including the Integrated Medication Management Program and the Coast Mental Health Medication Program.

• Anastasia Frank ? Research Coordinator
  Ms. Frank holds a Master of Public Health from the University of British Columbia and a BA with Honours in Geography from McGill University. Her focus is expanding the links between urban planning and public health. She has worked on a number projects both in and out of the lab.

Canadian clinical trials are planned for Q3 2017 pending approval of a New Drug Submission by the Health Products and Food Branch of Health Canada.

Blake and Sajo are continuing to negotiate key terms of the joint venture. The two companies entered into an agreement about one week ago but have agreed to renegotiate certain terms. 

About Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.
  
About Blake Insomnia Therapeutics Inc.
Blake is a pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company's patent-pending ZLX-1 compound has demonstrated efficacy without producing side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepaxtm.

Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.